| 摘要 |
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to medicine and pharmacology and represents combination for treatment of respiratory tract diseases, including bronchial asthma and chronic obstructive lung disease, characterised by the fact that it consists of local R,R-glycopyrrolate or its physiologically acceptable salts and phosphodiesterase 4 inhibitors or their physiologically acceptable salts. ^ EFFECT: invention ensures bronchospasmolytic effect, as well as superadditive anti-inflammatory effect. ^ 17 cl, 1 ex |
